OBJECTIVES

: While emerging treatments would prolong survival of chronic myeloid leukemia (CML) which has a substantial impact on patient well-being, these treatments also result in additional monetary costs. Reliable data on individual preference (utility) would be required to accurately evaluate the value of innovative treatments to support payer decision-making. A systematic literature review was therefore conducted to identify and review utility values estimated for CML.

METHODS

Both English (PubMed, MEDLINE) and Chinese (CNKI, Wan-Fang) databases were searched to identify relevant literatures that reported health utility values for CML published between 2000 and December 2020. The review included different types of respondents and utility measurements. The literatures were categorized by country, population of respondents, and utility methods.

RESULTS

: Of the 175 studies identified, 164 were excluded due to missing data (90), irrelevant outcomes (61), irrelevant population (7) and language (6). 11 studies were finally included. EQ-5D was the most commonly used instrument (7), whilst TTO method (3) and SF-36 (1) instruments were also employed. Of the 11 studies, only 3 were conducted in the general public population and the rest were in CML patients in clinical study where treatment-specific utility values were evaluated, which might have potential bias due to patient vested interests. Of the 11 studies, 4 were conducted in UK and 2 were in US. Only one study was conducted in Chinese CML patients using SF-36.

CONCLUSIONS

: The published utility studies were mainly in CML patients outside China, CML health state preference weights from Chinese general population were lacking Preference difference due to population demographics and sociocultural characteristics may lead to significant differences in utility values. To perform economic evaluations of innovative treatments for Chinese payers, building utility values reflecting Chinese population-based preferences is an urgent needs.